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A b s t r a c t
Background: Conflicting results have been presented regarding the influence of body mass index (BMI) on outcomes among 
patients undergoing transcatheter aortic valve implantation (TAVI).
Aims: To investigate the impact of BMI on clinical outcomes after TAVI.
Methods: A total of 148 consecutive patients were categorised using baseline BMI according to the World Health Organization 
criteria. Baseline patient characteristics, frailty, and procedural and clinical outcomes including 30-day and 12-month all-cause 
mortality were compared between the BMI categories. Patients were followed up for a median of 460.0 (182.0–1042.0) days.
Results: Obesity was diagnosed in 37 (25.2%) patients, 73 (49.7%) patients were overweight, and 37 (25.2%) had normal 
weight. Prevalence of lower frailty as assessed by five-metre walk test was confirmed in obese patients as compared to 
other groups. A trend towards a lower rate of in-hospital bleeding complications (18 [48.6%] vs. 21 [28.8%] vs. 9 [24.3%] 
in normal-weight, overweight, and obese patients, respectively; p = 0.06) and less frequent blood transfusions (18 [48.6%] 
vs. 17 [23.3%) vs. 8 [21.6%]; p = 0.016) was observed in overweight and obese groups. The rate of grade 3 acute kidney 
injury was lowest in the overweight group (4 [10.8%] vs. 1 [1.4%] vs. 3 [8.1%]; p = 0.05). There was no difference between 
the groups in terms of 30-day all-cause mortality (p = 0.15). However, 12-month all-cause mortality was lowest in obese pa-
tients (12 [32.4%] vs. 10 [13.7%] vs. 2 [5.4%]; p = 0.004). Increase in BMI was independently associated with lower all-cause 
mortality (hazard ratio [95% confidence interval] per 1 kg/m2 increase: 0.91 [0.845–0.98]; p = 0.018). 
Conclusions: Increased BMI was independently associated with survival benefit after TAVI. 
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INTRODUCTION
Obesity is as a major modifiable risk factor for an increased 
risk of cardiovascular morbidity and mortality [1]. Despite their 
detrimental effects on general health status, overweight and 
obesity were linked with a protective effect in a wide range of 
cardiovascular interventions [2–5]. This discrepancy was also 
reported in patients with severe aortic stenosis (AS) undergo-
ing transcatheter aortic valve implantation (TAVI) [3, 6–12]. 
However, some studies reported no effect of body mass index 
(BMI) on outcomes in patients undergoing TAVI [13, 14]. The 
validated mechanisms of this obesity paradox are elusive. How-
ever, several possible explanations were postulated, including 
the paracrine effect of the adipose tissue [15]. Importantly, the 
number of obese patients with severe AS scheduled for TAVI is 
substantial and will continually increase as a result of the aging of 
the population. Thus, we sought to evaluate the impact of BMI 
on clinical outcomes after TAVI and to determine the validity 
of the obesity paradox in this group of patients.
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METHODS
Data on 148 consecutive patients with symptomatic severe AS 
scheduled for TAVI, who were considered inoperable or too 
high-risk for a conventional surgical aortic valve replacement, 
were collected between the years 2008 and 2015 [10]. The 
height and weight of all the patients were measured by medi-
cal staff on admission. The BMI was calculated as the body 
mass in kilograms divided by the square of the height in metres 
(kg/m2). Patients were stratified according to BMI categories 
adopted from the World Health Organization and National 
Institutes of Health guidelines and classified as underweight 
(≤ 18.4 kg/m2), normal-weight (18.5–24.9 kg/m2), overweight 
(25.0–29.9 kg/m2), or obese (≥ 30 kg/m2) [16]. Frailty evalua-
tion was described previously [10]. The assessment of adverse 
events was in accordance with the Valve Academic Research 
Consortium (VARC)-2 definitions [17]. A local institutional 
ethical board approved the research protocol, and written, 
informed consent was obtained from all participants. Patient 
anonymity was preserved. The study was conducted according 
to the ethical guidelines of the 1975 Declaration of Helsinki 
with later amendments.
Statistical analysis
Categorical variables were expressed as number of patients 
(percentage) and compared using the c2 or Fisher exact test 
as appropriate. Median and interquartile range (IQR) were 
used for continuous variables, which were compared using the 
Kruskal-Wallis test. Differences in outcomes were presented 
as age-/sex-adjusted odds ratios (ORs) with 95% confidence 
intervals (CIs). Survival was estimated using the Kaplan-Meier 
method according to BMI categories. Furthermore, a multi-
variate Cox proportional hazards model was constructed to 
identify independent predictors of all-cause mortality during 
maximal follow-up. All baseline variables were considered 
(age, sex, BMI, estimated glomerular filtration rate, arterial 
hypertension, diabetes mellitus, atrial fibrillation, previous 
myocardial infarction, previous percutaneous coronary in-
tervention, previous coronary artery bypass grafting, chronic 
obstructive pulmonary disease, incomplete revascularisa-
tion, previous stroke/transient ischaemic attack, pacemaker 
implantation, logistic EuroSCORE I, the Society of Thoracic 
Surgeons [STS] score, left ventricular ejection fraction, systolic 
pulmonary artery pressure ≥ 46 mmHg, and access type), 
and a probability value for covariates to enter the model was 
set at the level of 0.10. The results are presented as hazard 
ratios (HRs) adjusted for age/sex with associated 95% CI. 
Two-sided p-values < 0.05 were considered significant in all 
analyses. The SPSS 15.0 statistical package (SPSS, Inc., Chi-
cago, IL, USA) was used to perform all statistical calculations.
RESULTS
The population consisted of 148 consecutive patients 
who underwent TAVI due to severe AS. One patient with 
BMI ≤ 18.4 kg/m2 was excluded from the analysis. Of the 
remaining 147 patients, 37 (25.2%) were obese, 73 were 
classified as overweight (49.7%), and 37 (25.2%) had normal 
weight. The median BMI was 27.0 kg/m2 (24.9–30.1 kg/m2). 
Overall, obese patients were younger, with lower prevalence 
of incomplete coronary revascularisation (Table 1). Similar 
rates of comorbidities, except for previous stroke/transient 
ischaemic attack, were reported in all BMI categories. Mean 
transvalvular gradient before TAVI was highest in the 
overweight group (Table 1). Importantly, no differences in 
periprocedural risk measured with logistic EuroSCORE and 
the STS score were noted. Furthermore, the prevalence of 
lower frailty as assessed with five-metre walk test (5MWT) 
was observed in obese patients as compared to the over-
weight and normal-weight groups (Table 2). Procedural and 
echocardiographic data after TAVI are shown in Table 3. The 
median length of hospital stay was comparable between the 
groups (10.0 [8.0–14.0] vs. 10.0 [7.0–13.0] vs. 10.0 [8.5–11.5] 
days for normal-weight, overweight, and obese patients, 
respectively; p = 0.5). 
The patients were followed up for a median of 
460.0 (182.0–1042.0) days. A trend towards a lower rate of 
in-hospital bleeding complications in overweight and obese 
patients was observed, with lower rates of blood transfusions in 
these groups as compared to normal-weight patients (Fig. 1A). 
No difference in antiplatelet or antithrombotic therapy on 
discharge was observed (Table 3). The rate of grade 3 acute 
kidney injury (AKI) was lowest in the overweight group 
(4 [10.8%] vs. 1 [1.4%] vs. 3 [8.1%]; p = 0.05). However, there 
was no difference between the groups in terms of all-cause 
mortality at 30 days. At 12 months, comparable rates of cer-
ebrovascular incidents, myocardial infarction, new permanent 
pacemaker implantation, and new onset of atrial fibrillation 
were observed in all groups (Fig. 1B). The rate of 12-month 
all-cause mortality was lower in obese patients than in those 
with normal BMI and overweight (12 [32.4%] vs. 10 [13.7%] 
vs. 2 [5.4%]; p = 0.004; Fig. 2). Furthermore, lower mortal-
ity in this group was confirmed in patients undergoing TAVI 
through the femoral access (12-month all-cause mortality: 
29.2% vs. 11.9% vs. 5.9%; p = 0.03), while no effect was 
reported for the transapical access (45.5% vs. 23.1% vs. 0.0%; 
p = 0.35). A list of all variables included in the univariate 
analysis model for mortality is presented in Table 4. Finally, in 
the Cox regression model, increase in BMI was independently 
associated with lower all-cause mortality (HR [95% CI] per 
1 kg/m2 increase: 0.91 [0.845–0.98]; p = 0.018) (Table 4).
DISCUSSION
The results of our study suggest a better survival in obese and 
overweight patients as compared to those with normal BMI. 
Also, an analysis of postprocedural complications indicates 
a superior outcome in these patients; there was a trend 
towards a lower rate of in-hospital bleeding complications 
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and less frequent blood transfusions in the overweight and 
obese. In contrast to most other studies, the rate of grade 3 
AKI was lowest in the overweight group. Thus, these data 
may support the presence of the suggested obesity paradox in 
patients undergoing TAVI [3, 6, 11, 12]. However, some other 
studies presented contradictory results, implying no influence 
of BMI on the prognosis after TAVI [13, 14, 18]. Despite the 
similar median value of BMI, overweight/obese groups were 
represented by a lower percentage of the whole population as 
compared with our study [13, 14, 18]. Lower periprocedural 
risk and rate of comorbidities in overweight/obese patients 
were not connected with differences in survival among BMI 
categories [13, 14, 18]. Furthermore, higher mortality was 
observed in underweight but not in overweight/obese pa-
tients as compared to the normal BMI group [18]. Low BMI 
was identified as an independent predictor of mortality after 
adjustment for covariates [18]. In contrast, a recent propensity 
score matching analysis cast doubt on this outcome in the 
TAVI population [19]. However, this study assessed the impact 
of BMI < 20 kg/m2 defined as indicative of frailty according 
to VARC-2; thus, the results were not directly related to the 
underweight category [17, 19]. In our study the underweight 
group was too small to enable the evaluation of outcomes; 
thus, it was excluded from the analysis. 
In contrast to the above findings, a recent study presented 
a positive linear relationship with mortality risk reduction for 
Table 1. Baseline characteristics and echocardiographic data of the patients
Variable Weight categories p
Normal 
(n = 37)
Overweight 
(n = 73)
Obese 
(n = 37)
Age [years] 83.0 (78.0–85.0) 83.0 (79.0–86.0) 78.0 (77.0–82.0) 0.007
Age ≥ 80 years 24 (64.9) 51 (69.9) 17 (45.9) 0.045
Male sex 19 (51.4) 26 (35.6) 10 (27.0) 0.09
Estimated GFR [mL/min/1.73 m2] 54.0 (37.0–73.5) 56.5 (43.8–71.0) 61.0 (37.5–76.0) 0.93
Arterial hypertension 36 (97.3) 69 (94.5) 33 (89.2) 0.36
Diabetes mellitus 9 (24.3) 26 (35.6) 13 (35.1) 0.48
Atrial fibrillation 13 (35.1) 23 (31.5) 15 (40.5) 0.67
Previous MI 11 (29.7) 25 (34.2) 12 (32.4) 0.92
Previous PCI 11 (29.7) 20 (27.4) 12 (32.4) 0.87
Previous CABG 4 (10.8) 15 (20.5) 8 (21.6) 0.43
COPD 3 (8.1) 11 (15.1) 5 (13.5) 0.66
Chronic total occlusion 4 (10.8) 9 (12.3) 1 (2.7) 0.27
Incomplete revascularisation 10 (27.0) 10 (13.7) 2 (5.4) 0.030
Previous stroke/TIA 8 (21.6) 4 (5.5) 5 (13.5) 0.037
Pacemaker 6 (16.2) 5 (6.8) 6 (16.2) 0.18
Logistic EuroSCORE I [%] 11.6 (9.7–17.8) 17.0 (11.4–23.0) 15.0 (8.0–22.0) 0.08
STS score [%] 6.0 (4.0–14.0) 6.4 (4.1–18.0) 6.5 (4.0–18.0) 0.83
Maximal transvalvular gradient [mmHg] 83.0 (60.0–101.0) 89.0 (77.0–106.5) 81.5 (64.0–93.0) 0.06
Mean transvalvular gradient [mmHg] 48.0 (34.0–60.0) 53.0 (44.0–66.0) 48.0 (40.5–53.0) 0.028
Aortic valve area [cm2] 0.7 (0.6–0.8) 0.7 (0.5–0.8) 0.7 (0.6–0.8) 0.18
LVEF [%] 60.0 (50.0–65.0) 60.0 (50.0–65.0) 55.0 (48.0–65.0) 0.87
Aortic regurgitation: 0.16
None 17 (45.9) 18 (24.7) 13 (35.1)
Mild 14 (37.8) 45 (61.6) 16 (43.2)
Moderate 5 (13.5) 7 (9.6) 7 (18.9)
Severe 1 (2.7) 3 (4.1) 1 (2.7)
SPAP ≥ 46 mmHg 16 (43.2) 23 (31.5) 14 (37.8) 0.48
Data are presented as number (percentage) or median (interquartile range). CABG — coronary artery bypass grafting; COPD — chronic obstructive 
pulmonary disease; GFR — glomerular filtration rate; LVEF — left ventricular ejection fraction; MI — myocardial infarction; PCI — percutaneous 
coronary intervention; SPAP — systolic pulmonary artery pressure; STS — Society of Thoracic Surgeons; TIA — transient ischaemic attack
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Table 2. Frailty indices in all body mass index categories
Frailty evaluation tool Frailty index Weight categories p
Normal 
(n = 37)
Overweight 
(n = 73)
Obese 
(n = 37)
5-metre walk test [s] ≥ 6, frail 10 (27.0) 9 (12.3) 2 (5.4) 0.020
Elderly mobility scale [points] < 10, frail 3 (8.1) 3 (4.1) 2 (5.4) 0.27
10–13 27 (73.0) 45 (61.6) 20 (54.1)
> 13 7 (18.9) 25 (34.2) 15 (40.5)
Canadian Study of Health and Aging scale [points] 1–3 19 (51.4) 47 (64.4) 21 (56.8) 0.40
4 10 (27.0) 20 (27.4) 13 (35.1)
5, frail 2 (5.4) 1 (1.4) 0 (0.0)
6–7, frail 6 (16.2) 5 (6.8) 3 (8.1)
Katz index [points] < 6, frail 8 (21.6) 7 (9.6) 4 (10.8) 0.23
Grip strength [grade] Weak, frail 3 (8.1) 2 (2.7) 2 (5.4) 0.47
Mild 5 (13.5) 5 (6.8) 4 (10.8)
Strong 29 (78.4) 66 (90.4) 31 (83.8)
Identification of Seniors at Risk scale [points] ≥ 2, functional 
decline, frail
14 (37.8) 27 (37.0) 12 (32.4) 0.90
Data are presented as number (percentage).
Table 3. Procedural and echocardiographic data, and treatment after the procedure
Variable Weight categories p
Normal 
(n = 37)
Overweight 
(n = 73)
Obese 
(n = 37)
Access type: 0.047
Transfemoral 24 (64.9) 59 (80.8) 34 (91.9)
Transapical 11 (29.7) 13 (17.8) 3 (8.1)
Transaortic 1 (2.7) 1 (1.4) 0 (0.0)
Subclavian 1 (2.7) 0 (0.0) 0 (0.0)
Maximal transvalvular gradient [mmHg] 12.8 (10.1–19.0) 14.0 (10.0–18.0) 15.0 (10.0–19.5) 0.84
Median transvalvular gradient [mmHg] 7.0 (6.0–11.0) 7.4 (5.0–10.0) 8.0 (6.0–10.5) 0.88
LVEF [%] 48.5 (40.0–55.0) 48.0 (44.0–57.5) 50.0 (42.0–55.0) 0.90
Paravalvular leak: 0.84
None 21 (56.8) 41 (56.2) 21 (56.8)
Mild 13 (35.1) 28 (38.4) 14 (37.8)
Moderate 3 (8.1) 2 (2.7) 2 (5.4)
Severe 0 (0.0) 2 (2.7) 0 (0.0)
Antiplatelet and antithrombotic therapy  
on discharge after the procedure:
0.9
Triple antithrombotic therapy 10 (27.0) 13 (17.8) 8 (21.6)
Dual antiplatelet therapy 16 (43.2) 35 (47.9) 16 (43.2)
ASA alone 8 (21.6) 16 (21.9) 7 (18.9)
Oral anticoagulant with ASA 3 (8.1) 9 (12.3) 6 (16.2)
Data are presented as number (percentage) or median (interquartile range). ASA — acetylsalicylic acid; LVEF — left ventricular ejection fraction
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every increase of one unit of BMI [6]. Other studies reported 
better survival among the overweight/obese patients in both 
30-day and 12-month observation [6, 11]. However, some 
analyses presenting a beneficial outcome in the obese/over-
weight groups included a smaller percentage of patients with 
BMI ≥ 25 kg/m2 in comparison with our study [3, 11]. Finally, 
a recent large meta-analysis presented similar rates of 30-day 
and long-term all-cause mortality in overweight as compared 
with normal-weight patients [20]. Likewise, no differences in 
30-day survival and procedural complications were observed 
between the obese and normal BMI categories [20]. However, 
lower mortality among the obese in long-term follow-up was 
confirmed (HR 0.79; 95% CI 0.67–0.93; p = 0.004) [20]. 
Another meta-analysis presented an association between 
obesity/overweight and favourable outcome in TAVI patients 
for both continuous and categorised BMI values [21]. Interest-
ingly, a different study postulated that weight change before 
TAVI is a more relevant marker of outcome than absolute 
weight at the time of the procedure [22]. Furthermore, BMI 
category was not correlated with mortality in patients with 
stable weight at the time of TAVI [22]. Body weight change 
was not captured in our study. 
Figure 2. Kaplan-Meier curves for survival after transcatheter 
valve implantation stratified by body mass index categories;  
CI — confidence interval; HR — hazard ratio
Figure 1. In-hospital/30-day (A) and 12-month (B) outcomes after transcatheter valve implantation stratified by body mass  
index categories; AF — atrial fibrillation; AKI — acute kidney injury; CV — cerebrovascular; MI — myocardial infarction;  
*30-day mortality
A
B
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The inconsistencies regarding the obesity paradox in 
TAVI populations might be related to differences in the cat-
egorisation of BMI as a variable (continuous or categorical) 
and different definitions of obesity. The protective effects of 
obesity/overweight in our study might be partially linked to 
the coexisting differences in age and comorbidities between 
the groups. These observations seem to be more important 
in combination with the independent predictors of mortality 
identified in our study. Intuitively, obesity might lead to higher 
prevalence of access-site and bleeding complications as well 
as blood transfusion, but this association was not established 
in our study. Most of the studies confirmed no differences in 
AKI and bleeding or vascular complication incidence between 
BMI categories [3, 14, 20, 23]. A trend towards worse renal 
function and more periprocedural complications in obese 
patients was reported by De Palma et al. [22]; however, 
the percentage of obese patients in their study was relatively 
small. Furthermore, obesity was associated with higher in-
cidence of vascular complications and bleeding, whereas 
blood transfusions were more common in the normal-weight 
group [6]. The obese patients had a higher prevalence 
of comorbidities, including diabetes mellitus [6]. A link 
between major vascular and bleeding complications and 
insulin-treated diabetes was reported [24, 25]. Improved 
operator skills and a reduction in sheath and valve sizes may 
be partially responsible for the decreased rate of vascular 
complications as compared to previous studies. Several 
reports demonstrated a link between blood transfusion and 
mortality following TAVI [26, 27]. In our study, a higher 
prevalence of AKI in patients defined as normal-weight was 
observed. A recent study proved that bleeding complications 
and blood transfusion were predictors of AKI [27]. In addi-
tion, the detrimental effect of red blood cell transfusion on 
AKI and long-term survival was associated with an increased 
number of transfusions [28]. 
Despite all the above factors affecting the outcome, the 
mechanism behind the obesity paradox in the TAVI popula-
tion is still unclear. Some might argue that the obese group 
consisted of younger patients with potentially lower proce-
dural risk and hence the outcomes have been biased. Younger 
patients might seek medical care earlier, thus a more aggressive 
treatment with cardioprotective drugs could lead to a benefi-
cial outcome of interventional treatment [5, 15]. However, 
in our study increased BMI was identified as an independent 
predictor of improved survival even after adjusting for age 
and sex. Several studies have also shown that the population 
with increased BMI received more optimal medical treatment 
compared with those with a normal BMI [15]. Investigators 
denying the obesity paradox postulated an incremental role 
of metabolic reserve in resistance of detrimental effects of 
acute morbidities or procedural stress [3, 5, 15]. Another pos-
sible protective mechanism relies on higher level of tumour 
necrosis factor alpha (TNF-a) receptor produced by exces-
sive adipose tissue [3, 5, 15, 29]. Thus, the adverse effect 
of increasing TNF-a in patients with chronic inflammation 
diseases is neutralised [29]. Likewise, an enhanced level of 
circulating lipoproteins may counteract lipopolysaccharides 
stimulating the production of inflammatory cytokines [5, 15]. 
A possible explanation for the discrepancy in survival might 
be also connected with frailty indices. In our study, obese 
and overweight patients had a lower rate of frailty measured 
with 5MWT as compared to normal BMI patients. It could be 
a potential marker of better mobility and general health status 
in this group. The evaluation of frailty as well as quality of life 
[30] have been presented as important factors of overall health 
status in TAVI patients [10, 31]. However, BMI does not enable 
the discrimination between the components of body or the 
type and location of fat tissue. To avoid potential limits of BMI, 
frailty should be evaluated to anticipate the potential futility 
of TAVI. Currently, BMI is not incorporated in commonly used 
Table 4. Univariate and multivariate analysis models for  
mortality
Variable HR 95% CI
Univariate analysis:
Age 1.024 0.973–1.079
Male sex 2.452 1.212–4.959
BMI 0.923 0.851–1.001
eGFR 0.972 0.954–0.991
Arterial hypertension 0.915 0.218–3.847
Diabetes mellitus 1.443 0.710–2.931
Atrial fibrillation 0.916 0.431–1.948
Previous MI 1.500 0.730–3.081
Previous PCI 1.974 0.977–3.989
Previous CABG 0.288 0.068–1.218
COPD 2.436 1.111–5.341
Incomplete revascularisation 7.607 3.727–15.527
Previous stroke/TIA 3.966 1.789–8.795
Pacemaker implantation 0.878 0.266–2.896
Logistic EuroSCORE I 1.020 0.981–1.061
STS score 0.993 0.953–1.035
LVEF 1.002 0.972–1.032
SPAP ≥ 46 mmHg 1.537 0.749–3.154
Access type (femoral vs. other) 0.783 0.349–1.758
Multivariate analysis
BMI 0.91 0.845–0.98
Incomplete revascularisation 5.322 2.389–11.853
eGFR 0.961 0.94–0.984
Previous stroke/TIA 3.988 1.644–9.674
BMI — body mass index; CI — confidence interval; eGFR — estimated 
glomerular filtration rate; HR — hazard ratio; other abbreviation — see 
Table 1
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risk scores aimed at predicting mortality after TAVI. However, 
the available data may suggest the inclusion of this measure 
in new TAVI-oriented risk score models.
The study has all the limitations of a single-centre regis-
try. The observational nature of this study could not provide 
clear evidence of an association between increased BMI and 
survival benefit, and causality could not be established. BMI 
was used only to categorise patients into the obese/overweight 
group. However, a combination of BMI with central obesity 
assessment (waist-to-hip ratio, triceps skinfold thickness, or 
waist circumference) could be more valuable in the evaluation 
of survival benefit after TAVI [3]. Because the change in body 
weight during follow-up was not captured, the potential im-
pact of body mass change on outcomes cannot be excluded. 
Importantly, weight was measured after the onset of the dis-
ease with potential concomitant fluid retention. Thus, it may 
have not represented the true “dry weight” of the body and 
may have overestimated BMI with erroneous categorisation 
to the obese or overweight group. 
In conclusion, increased BMI was independently associ-
ated with survival benefit after TAVI. Therefore, our results 
may support the presence of so-called obesity paradox in the 
TAVI population.
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WHAT IS NEW?
We demonstrated that 12-month all-cause mortality after transcatheter aortic valve implantation was lower in obese 
patients as compared to normal-weight and overweight groups. However, there was no difference in 30-day survival 
between body mass index categories. Increase in body mass index was independently associated with lower all-cause 
mortality after this procedure. A trend towards a lower rate of in-hospital bleeding complications and less frequent blood 
transfusions in overweight and obese patients was observed. The rate of grade 3 acute kidney injury was lowest in the 
overweight group. Body mass index is not incorporated in commonly used risk scores to predict mortality after transcath-
eter aortic valve implantation. However, the available data supporting the presence of the so-called obesity paradox 
may suggest inclusion of this measure in new risk score models oriented towards transcatheter aortic valve implantation.
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